SummaryRMgm-371
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene tagging |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 20059687 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. yoelii |
Parent strain/line | P. y. yoelii 17XNL |
Name parent line/clone | Not applicable |
Other information parent line | 17XNL is a non-lethal strain of P. yoelii |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | Y. Pei; S.H.I. Kappe |
Name Group/Department | Not applicable |
Name Institute | Seattle Biomedical Research Institute, University of Washington |
City | Seattle |
Country | USA |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-371 |
Principal name | PDH E1α-myc |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Not different from wild type |
Fertilization and ookinete | Not different from wild type |
Oocyst | Not different from wild type |
Sporozoite | IFA analyses using anti-myc antibodies showed no significant expression in blood stages. PHD E1α-myc expression was observed in salivary gland sporozoites. The myc-tagged protein was localized to a small circular structure next to the nucleus. IFA analyses demonstrated the co-localization of E1α-myc with FabI, a FAS II elongation enzyme that is expressed in the apicoplast, confirming that PDH is targeted to the apicoplast. |
Liver stage | In liver stages E1α-myc staining was observed at 24 hour as tadpole-shaped structures surrounding the dividing nuclei. Liver stages exhibited intensive staining at 30 and 43 hi, which coincides with the extensive expansion of the apicoplast during schizogony. At 52 hi, E1α-myc expression appeared as small dots in a similar number and size to the individual nuclei present in the developing merozoites. |
Additional remarks phenotype | Mutant/mutation In previous studies it has been shown that apicoplast-targeted proteins include enzymes of the FAS II pathway. The presence of this pathway indicates that as well as taking up lipids from its host, Plasmodium also utilizes its own de novo fatty acid synthesis. Transcriptome and proteome analyses of Plasmodium liver stages have demonstrated the expression of apicoplast-targeted enzymes involved in FAS II in liver stages, indicating an important role of de novo FAS II in the developing liver stage. It has been shown that deletion of genes encoding FAS II elongation enzymes (i.e. FabI, FabB/F, FabZ.) caused no defects in parasite blood stage replication and mosquito stage development but liver stage development was severely reduced in the FAS II-deficient parasites. Phenotype analyses of mutants lacking expression of PDH E1α (RMgm-376, RMgm-378). indicate a non-essential role of PDH E1α for blood stages and mosquito stages but an important role during late liver stage development. Analysis of in vitro cultured liver stages showed significant defects in terms of growth and nuclear division. Disruption of PDH E1α showed a similar phenotype to mutants lacking FAS II elongation enzymes (i.e. FabI, FabB/f; FabZ). This suggests that in Plasmodium the sole function of PDH is to provide the acetyl-CoA necessary for de novo fatty acid synthesis. Phenotype |
top of page | |||||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||||
Gene Model of Rodent Parasite | PY17X_0925800 | ||||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1124500 | ||||||||||||||||||||||||||
Gene product | pyruvate dehydrogenase E1 component subunit alpha | ||||||||||||||||||||||||||
Gene product: Alternative name | PDH E1α | ||||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||||
Name of the tag | c-myc | ||||||||||||||||||||||||||
Details of tagging | C-terminal | ||||||||||||||||||||||||||
Additional remarks: tagging | quadruple myc tag | ||||||||||||||||||||||||||
Commercial source of tag-antibodies | Santa Cruz Biotechnology (anti-myc primary) Invitrogen (Alexa fluor secondary) | ||||||||||||||||||||||||||
Type of plasmid/construct | Plasmid single cross-over | ||||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||||
Restriction sites to linearize plasmid | NcoI | ||||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||||
Additional remarks genetic modification | To generate the E1α-myc transgenic parasite line, the P. yoelii PDH e1α gene without the stop codon, as well as approximately 1.5 kb upstream sequence from the start codon, was amplified by PCR from P. yoelii 17XNL genomic DNA and was cloned upstream of the quadruple myc tag in plasmid b3D-myc. The plasmid was subsequently linearized with NcoI and integrated into the P. yoelii 17XNL genome by single crossover recombination. This integration strategy created two copies of the e1α gene, which were both under the control of the endogenous promoter. One copy is the original gene and the other is the myc epitope-tagged gene. | ||||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
top of page |